290 related articles for article (PubMed ID: 25637408)
1. Systematic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients.
Bloem K; van Leeuwen A; Verbeek G; Nurmohamed MT; Wolbink GJ; van der Kleij D; Rispens T
J Immunol Methods; 2015 Mar; 418():29-38. PubMed ID: 25637408
[TBL] [Abstract][Full Text] [Related]
2. Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation.
van Schouwenburg PA; Krieckaert CL; Rispens T; Aarden L; Wolbink GJ; Wouters D
Ann Rheum Dis; 2013 Oct; 72(10):1680-6. PubMed ID: 23300118
[TBL] [Abstract][Full Text] [Related]
3. Antidrug antibody detection for adalimumab depends on the type of assay used: an experimental approach to help clinicians interpret diagnostic data.
Ruwaard J; Marsman AF; Nurmohamed MT; van der Horst-Bruinsma IE; Te Velthuis H; Bloem K; de Vries A; Rispens T; Wolbink G
Clin Exp Rheumatol; 2019; 37(5):756-761. PubMed ID: 30943139
[TBL] [Abstract][Full Text] [Related]
4. A novel method for the detection of antibodies to adalimumab in the presence of drug reveals "hidden" immunogenicity in rheumatoid arthritis patients.
van Schouwenburg PA; Bartelds GM; Hart MH; Aarden L; Wolbink GJ; Wouters D
J Immunol Methods; 2010 Oct; 362(1-2):82-8. PubMed ID: 20833178
[TBL] [Abstract][Full Text] [Related]
5. Differential effect of drug interference in immunogenicity assays.
Hart MH; de Vrieze H; Wouters D; Wolbink GJ; Killestein J; de Groot ER; Aarden LA; Rispens T
J Immunol Methods; 2011 Sep; 372(1-2):196-203. PubMed ID: 21824477
[TBL] [Abstract][Full Text] [Related]
6. A breakthrough novel method to resolve the drug and target interference problem in immunogenicity assays.
Zoghbi J; Xu Y; Grabert R; Theobald V; Richards S
J Immunol Methods; 2015 Nov; 426():62-9. PubMed ID: 26255760
[TBL] [Abstract][Full Text] [Related]
7. Drug interference in immunogenicity assays depends on valency.
Rispens T; Hart MH; Ooijevaar-de Heer P; van Leeuwen A; Vennegoor A; Killestein J; Wolbink GJ; van der Kleij D
J Pharm Biomed Anal; 2013 Nov; 85():179-85. PubMed ID: 23954437
[TBL] [Abstract][Full Text] [Related]
8. Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation.
van Schouwenburg PA; van de Stadt LA; de Jong RN; van Buren EE; Kruithof S; de Groot E; Hart M; van Ham SM; Rispens T; Aarden L; Wolbink GJ; Wouters D
Ann Rheum Dis; 2013 Jan; 72(1):104-9. PubMed ID: 22759910
[TBL] [Abstract][Full Text] [Related]
9. Drug-tolerant detection of anti-drug antibodies in an antigen-binding assay using europium chelate fluorescence.
van Strien J; Dijk L; Atiqi S; Schouten R; Bloem K; Wolbink GJ; Loeff F; Rispens T
J Immunol Methods; 2023 Mar; 514():113436. PubMed ID: 36716916
[TBL] [Abstract][Full Text] [Related]
10. Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52 weeks of follow-up.
Vogelzang EH; Kneepkens EL; Nurmohamed MT; van Kuijk AW; Rispens T; Wolbink G; Krieckaert CL
Ann Rheum Dis; 2014 Dec; 73(12):2178-82. PubMed ID: 25115447
[TBL] [Abstract][Full Text] [Related]
11. Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity.
Krieckaert CL; Jamnitski A; Nurmohamed MT; Kostense PJ; Boers M; Wolbink G
Arthritis Rheum; 2012 Dec; 64(12):3850-5. PubMed ID: 22933315
[TBL] [Abstract][Full Text] [Related]
12. Development of an ELISA-Based Competitive Binding Assay for the Analysis of Drug Concentration and Antidrug Antibody Levels in Patients Receiving Adalimumab or Infliximab.
Hock BD; Stamp LK; Hayman MW; Keating PE; Helms ET; Barclay ML
Ther Drug Monit; 2016 Feb; 38(1):32-41. PubMed ID: 26222874
[TBL] [Abstract][Full Text] [Related]
13. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis.
Radstake TR; Svenson M; Eijsbouts AM; van den Hoogen FH; Enevold C; van Riel PL; Bendtzen K
Ann Rheum Dis; 2009 Nov; 68(11):1739-45. PubMed ID: 19019895
[TBL] [Abstract][Full Text] [Related]
14. Using monoclonal antibodies as an international standard for the measurement of anti-adalimumab antibodies.
van Schouwenburg PA; Kruithof S; Wolbink G; Wouters D; Rispens T
J Pharm Biomed Anal; 2016 Feb; 120():198-201. PubMed ID: 26748377
[TBL] [Abstract][Full Text] [Related]
15. IgG4 production against adalimumab during long term treatment of RA patients.
van Schouwenburg PA; Krieckaert CL; Nurmohamed M; Hart M; Rispens T; Aarden L; Wouters D; Wolbink GJ
J Clin Immunol; 2012 Oct; 32(5):1000-6. PubMed ID: 22622790
[TBL] [Abstract][Full Text] [Related]
16. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis.
Bartelds GM; Wijbrandts CA; Nurmohamed MT; Stapel S; Lems WF; Aarden L; Dijkmans BA; Tak PP; Wolbink GJ
Ann Rheum Dis; 2007 Jul; 66(7):921-6. PubMed ID: 17301106
[TBL] [Abstract][Full Text] [Related]
17. Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab.
Gorovits B; Baltrukonis DJ; Bhattacharya I; Birchler MA; Finco D; Sikkema D; Vincent MS; Lula S; Marshall L; Hickling TP
Clin Exp Immunol; 2018 Jun; 192(3):348-365. PubMed ID: 29431871
[TBL] [Abstract][Full Text] [Related]
18. Comparative study of both versions of an immunoassay commercialized for therapeutic drug monitoring of adalimumab in rheumatoid arthritis.
Llinares-Tello F; Rosas J; de la Torre I; Valor L; Barber X; Senabre JM;
Reumatol Clin; 2014; 10(2):105-8. PubMed ID: 24035361
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of interleukin-5 induced false positive anti-drug antibody responses against mepolizumab through the use of a competitive blocking antibody.
Liao K; Meyer E; Lee TN; Loercher A; Sikkema D
J Immunol Methods; 2017 Feb; 441():15-23. PubMed ID: 27889561
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the ELISA and ECL Assay for Vedolizumab Anti-drug Antibodies: Assessing the Impact on Pharmacokinetics and Safety Outcomes of the Phase 3 GEMINI Trials.
Wyant T; Yang L; Rosario M
AAPS J; 2020 Nov; 23(1):3. PubMed ID: 33200296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
